BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
Key Highlights
- ➤Net revenue $4,213 million, up 26.4% year over year
- ➤Adjusted EBITDA $228 million, up 42.0% year over year
- ➤Full-year revenue guidance raised to $15,900 million-$16,125 million
- ➤Full-year Adjusted EBITDA guidance raised to $850 million-$860 million
- ➤Leverage fell to 1.79x from 2.15x in the prior quarter
Expert Statements
Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring Health Services
“Our third quarter results again reflect the commitment of our team to patient care and operational execution across our Pharmacy and Provider businesses.”
Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring Health Services
“We have a differentiated company, our value proposition for healthcare stakeholders is clear, and our confidence in the future remains high, supported by a broad set of process and growth drivers across a uniquely scaled and high-quality platform.”
Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring Health Services
“As we progress through 2026, we believe that BrightSpring is well-positioned to make a greater and greater impact and deliver durable growth in 2027 and beyond.”
LOUISVILLE, Ky., Oct. 30, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home- and community-based health services for complex populations, today announced financial results for the third quarter ended September 30, 2026, and increased full year 2026 Revenue and Adjusted EBITDA(1) guidance.
Third Quarter 2026 Financial Highlights (note: on March 30, 2026, BrightSpring completed the divestiture of the Community Living business and, as such, all financial results provided pertain to continuing operations) * Net revenue of $4,213 million, up 26.4% compared to $3,334 million in the third quarter of 2025 * Gross profit of $519 million, up 32.3% compared to $392 million in the third quarter of 2025 * Net income from continuing operations of $101 million compared to $38 million in the third quarter of 2025 * Adjusted EBITDA(1) of $228 million, up 42.0% compared to $160 million in the third quarter of 2025 * Leverage of 1.79x as of September 30, 2026, compared to leverage of 2.15x on June 30, 2026 "Our third quarter results again reflect the commitment of our team to patient care and operational execution across our Pharmacy and Provider businesses," said Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring. "We have a differentiated company, our value proposition for healthcare stakeholders is clear, and our confidence in the future remains high, supported by a broad set of process and growth drivers across a uniquely scaled and high-quality platform. As we progress through 2026, we believe that BrightSpring is well-positioned to make a greater and greater impact and deliver durable growth in 2027 and beyond."
Get started
Create a free account to read the full story.